Veins and Lymphatics 2020-06-01T20:52:32+00:00 Paola Granata Open Journal Systems <p><strong>Veins and Lymphatics</strong>&nbsp;is an international, Open Access peer-reviewed journal which publishes scientific papers about venous and lymphatic diseases. Open issues and debates about epidemiology, anatomy, pathophysiology, etiology, diagnosis, treatment and prevention of vein and lymphatic diseases are constantly present in our project. A "transversal" vision of phlebology and lymphology is privileged, without preconception or barriers. Aiming at enhancing phlebolymphology culture diffusion worldwide, on a free access basis,&nbsp;<strong>Veins and Lymphatics</strong>&nbsp;wants to exploit internet capabilities for a large, quick and low-cost dissemination of educational and research inputs. Many specialties without one leading, are involved in this field of interest; we will try to encourage the clever connections between them for mutual advantage. A constant evolution has characterized Phlebology and Lymphology in the last decades so that “truisms” have been revised and criticized (see dogma of saphenectomy with junction high ligation). Novelties seem to come from different corners of the world, from doctors who are part of the scientific establishment, but also from those who have enough courage to break the conventional concepts. This journal will represent a medium for the rapid diffusion of these new ideas, on the basis of sound data and speculations. Nonetheless, “the new” advances whereas it is based on older fundaments, so we are not going to forget the strength of traditions and we will keep attention on the past acquisitions, to gain experience and impulse or, why not, to learn from others’ and our errors.&nbsp;</p> <p><strong>Veins and Lymphatics</strong>&nbsp;publishes original articles, editorials, reviews, short reports and case reports, as well as invited commentaries.</p> <p>&nbsp;</p> Acetazolamide and SGLT2 inhibitor as potent drugs for a patient with diabetes mellitus and worsening chronic lymphedema: A case report 2020-06-01T20:52:32+00:00 Hajime Kataoka <p>Treatment of lymphedema using a pharmacologic approach is reported to have limited efficacy. Here, I report a patient with type 2 diabetes (T2DM) and acute worsening of her chronic lymphedema, in whom treatment with acetazolamide and a sodiumglucose cotransporter-2 inhibitor (SGLT2i) effectively improved the lymphedema. A 94-year-old woman, who was treated for T2DM, hyperlipidemia, and hypertension for 17 years at my hospital presented to the emergency room because of acute worsening of her chronic right leg lymphedema with increased swelling, tightness, and dull aching. A pharmacologic approach was used to treat her worsening lymphedema. Acetazolamide 500 mg/d was administered to treat the acute tissue fluid collection in the right lymphedematous leg. Ten days later, the patient’s body weight was markedly reduced by 3.2 kg, pitting in the right leg was markedly improved, and the circumference of right limb was decreased. On day 11, the glucose-lowering agent vildagliptin was switched to the SGLT2i empagliflozin 10 mg/d. On day 70, her body weight had decreased further by 2.8 kg, and the circumference of her right limb was greatly reduced compared with that under treatment with acetazolamide. Her serum chloride concentration was increased after treatment, but her hemoglobin and hematocrit values did not change during the study period. In conclusion, acetazolamide and an SGLT2i have acute diuretic effects for draining the excess tissue fluid in the lymphedematous limb without vascular contraction by enhancing vascular tonicity. Additionally, an SGLT2i may have chronic effects for reducing fat deposits in the lymphedematous limb.</p> 2020-06-01T15:51:17+00:00 ##submission.copyrightStatement## Chronic cerebrospinal venous insufficiency, ten years after. New headlights on a venous disease that enriched the vascular world 2020-06-01T20:52:32+00:00 Pietro Maria Bavera <p>Two very recent scientific papers have re-opened a debate on a vascular issue,<em> chronic cerebrospinal venous insufficiency</em> (CCSVI), that apparently was sent in a corner by other trials and some Editorial hasty conclusions. The never-ending debate is still open and, perhaps, a one-year truce helped to calm waters and sort out, as by means of a sandbox, the situation from the vascular point of view. Before discussing why these recent papers have widened the path for CCSVI, some mind refreshing is mandatory, since the opinions are spread in all directions and a concise summary may help for those that are newcomers in this issue...</p> 2020-06-01T15:46:04+00:00 ##submission.copyrightStatement## COVID-19 Era: Mondor’s disease and Rembrandt. What ties? 2020-05-19T20:51:57+00:00 Giovanni B. Agus <p>The recent and increased number of scientific reports on venous thrombosis and venous thromboembolism induced by corona- virus, suggests to improve our level of attention because thrombophlebitis could be a clinical manifestation of COVID-19. We need to be aware also of rare varieties of venous thrombosis such as Mondor disease. The comparison between the enigmatic breast discoloration of the Bathsheba painted by Rembrandt and a case of Mondor disease observed in 2020, becomes a cultural game to improve our clinical skills in diagnosing Mondor thrombophlebitis.</p> 2020-05-19T11:00:31+00:00 ##submission.copyrightStatement##